For example, since TRAIL resistance of different hepatocellular carcinoma cellular models has been clearly associated to the aberrantly enhanced expression of antiapoptotic proteins belonging to Bcl-2 and IAPs families, siRNA based strategies seeking to selectively antagonize the expression of these proteins have been successfully developed to sensitize hepatocarcinoma cells to TRAIL based cancer therapy [96]. Here, BCL2 is linked to hepatocellular carcinoma.